– Dow Jones Citing WSJ
Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $12
Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $16 to $12.
‘Weapons Maker Offers Ukraine Reaper Drones For One Dollar’ – WSJ
– Dow Jones Citing WSJ
Related Posts
Activision Raises Alarm As FTC Considers Pausing Microsoft Takeover: ‘We Don’t See How This Will Continue’
Bobby Kotick, Activision Blizzard Inc's (NASDAQ: ATVI) CEO, said that the company would probably walk away from the $68.7 billion takeover bid by Microsoft Corp. (NASDAQ: MSFT) if the U.S.
Apple’s ‘Find My’ Feature Helps Police Track AirPods Allegedly Stolen From Canadian Hotel
Apple Inc.'s (NASDAQ: AAPL) Find My feature helped police track down AirPods allegedly stolen from a hotel in Boucherville, Canada.
Cedar Fair’s Strategic Merger with Six Flags Moves Forward Amid Record Guest Numbers and Financial Results
Cedar Fair reports 1% sales growth in Q4 of FY23, with net loss of $(10)M due to costs of proposed Six Flags merger. Attendance up 9%.